{
  "pmcid": "12148382",
  "abstract": "1. A 250-word version\n\nTitle: Electrocoagulation vs. Radiofrequency Ablation for Great Saphenous Vein: A Randomised Controlled Trial\n\nBackground: Thermoablation is increasingly used for treating primary varicose veins. This study compares the long-term outcomes of electrocoagulation ablation (EA) and radiofrequency ablation (RFA) of the great saphenous vein (GSV).\n\nMethods: In this double-blind, randomised controlled trial, 57 adults with primary chronic venous insufficiency were recruited from the Dante Pazzanese Institute of Cardiology and the Adventist Hospital of SÃ£o Paulo. Participants were randomly assigned to EA or RFA groups using sealed envelopes. The primary outcome was GSV occlusion, assessed via duplex ultrasound at 1 week, 3 months, 6 months, and annually. Secondary outcomes included complication rates and quality of life improvements, measured by the Aberdeen Varicose Vein Questionnaire. Blinding was maintained for patients and outcome assessors.\n\nResults: Between November 2014 and May 2016, 57 patients were randomised: 28 to EA and 29 to RFA. At 4.8 years, occlusion rates were 89.7% for EA and 66.7% for RFA (P = .001). No significant differences were found in complication rates or quality of life scores. Adverse events were similar between groups.\n\nInterpretation: EA demonstrated higher long-term GSV occlusion rates compared to RFA, with comparable safety and quality of life outcomes. Trial registration: NCT02139085. Funding: Dante Pazzanese Institute.",
  "word_count": 212
}